Safety, pharmacokinetics and pharmacodynamics of multiple‐dose noiiglutide ( SHR20004 ), a novel GLP ‐1 receptor agonist, in Chinese obese subjects without diabetes mellitus

Daily administration of noiiglutide using a titration method was well tolerated by Chinese obese participants without DM and showed potential therapeutic effect for weight loss.